Radiologic Imaging Procedure

PROCEDURE4 trials

Sponsors

National Cancer Institute (NCI), Jonsson Comprehensive Cancer Center

Conditions

Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast CarcinomaLocalized Estrogen Receptor-Positive Breast CarcinomaLocalized Human Epidermal Growth Factor Receptor (HER2)-Negative Breast CarcinomaLocally Advanced Breast Carcinoma

Phase 1

Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer

RecruitingNCT06654037

National Cancer Institute (NCI)Metastatic Microsatellite Stable Colorectal Carcinoma, Refractory Microsatellite Stable Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8

Start: 2025-04-18End: 2026-04-01Target: 39Updated: 2026-04-03

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

RecruitingNCT07137416

National Cancer Institute (NCI)Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma +13

Start: 2026-10-05End: 2028-01-10Target: 36Updated: 2026-04-03

Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma

Not yet recruitingNCT07422363

National Cancer Institute (NCI)Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma, Recurrent WHO Grade 4 Glioma

Start: 2026-06-28End: 2027-02-28Target: 30Updated: 2026-04-03

Phase 2

Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial

Not yet recruitingNCT07191717

Jonsson Comprehensive Cancer CenterAnatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 +3

Start: 2026-04-30End: 2031-04-30Target: 42Updated: 2025-11-10